Entrada Therapeutics(US:TRDA)2025-11-06 12:02Financial Position - Cash, cash equivalents, and marketable securities were $326.8 million as of September 30, 2025, down from $420.0 million as of December 31, 2024[6]. - The expected cash runway has been extended into Q3 2027, supported by the current cash position[1]. Revenue and Expenses - Collaboration revenue for Q3 2025 was $1.6 million, a significant decrease from $19.6 million in Q3 2024, primarily due to the completion of collaboration research activities related to VX-670[7]. - Research and development (R&D) expenses increased to $38.4 million in Q3 2025 from $31.3 million in Q3 2024, driven by costs associated with DMD programs and higher personnel costs[10]. - General and administrative (G&A) expenses rose to $10.3 million in Q3 2025 from $10.0 million in Q3 2024, mainly due to increased personnel costs[11]. - Total operating expenses for Q3 2025 were $48.7 million, compared to $41.2 million in Q3 2024[17]. - Net loss for Q3 2025 was $(44.1) million, compared to a net loss of $(14.0) million for the same period in 2024[11]. Clinical Development - The company is on track to report data from the first patient cohort of ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026[2]. - The company expects to initiate a Phase 1b MAD clinical study of ENTR-601-44 in the U.S. in the first half of 2026[8]. - The company filed for regulatory authorization in the U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50[1].